Vanguard Group Inc Neuro Metrix, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.61 - $0.98 $85,276 - $137,001	-139,797 Reduced 55.55%	111,851 $80,000
Q2 2023 Aug 14, 2023	SELL	$0.92 - $1.48 $90,610 - $145,765	-98,490 Reduced 28.13%	251,648 $244,000
Q4 2022 Feb 10, 2023	BUY	$1.36 - $22.72 $148 - $2,476	109 Added 0.03%	350,138 $521,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $23.6 $103,629 - $823,451	34,892 Added 11.07%	350,029 $977,000
Q1 2022 May 13, 2022	BUY	$3.42 - $6.37 $67,261 - $125,278	19,667 Added 6.66%	315,137 $1.31 Million
Q4 2021 Feb 14, 2022	SELL	$5.02 - $9.82 $406,685 - $795,547	-81,013 Reduced 21.52%	295,470 $1.48 Million
Q3 2021 Nov 12, 2021	BUY	$3.23 - $24.73 $1 Million - $7.67 Million	310,249 Added 468.41%	376,483 $3.82 Million
Q2 2021 Aug 13, 2021	BUY	$2.72 - $3.8 $180,156 - $251,689	66,234 New	66,234 $226,000

320

Ticker NURO
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 7,757,230
Market Cap $33.1M
Description
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to e...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.